Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIGB-300 in Stage IIA/IIB Cervical Cancer
NCT01639625Phase 2Completed
- Sponsor
- Laboratorio Elea Phoenix S.A.
- Start
- May 2011
- Primary completion
- Sep 2015
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of cigb-300 in Cervical Cancer (CC), sponsored by Laboratorio Elea Phoenix S.A.. Started May 2011; status: completed.
02
Drugs
cigb-300
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT01639625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01639625.